GlassScriptPhysician profile
Theodore Cm Li
NPI 1891857082
$3,925.33
in general payments reported to CMS, 2019-2025
38 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $434 · 2021: $666 · 2022: $563 · 2023: $572 · 2024: $728 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $653.02 | 2019-2025 | |
| Novo Nordisk INC | $529.81 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $366.34 | 2021-2025 | |
| Amgen INC. | $310.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Bausch Health US, LLC | $240.97 | 2019-2024 | Wellbutrin, Aplenzin |
| Lilly USA, LLC | $191.40 | 2020-2025 | Zepbound, Kisunla, Mounjaro |
| Merck Sharp & Dohme LLC | $145.43 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $130.01 | 2019-2024 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $111.46 | 2022-2025 | |
| Esperion Therapeutics, INC. | $96.53 | 2022-2025 | Nexletol |
| Allergan, INC. | $87.64 | 2019-2020 | |
| Astellas Pharma US INC | $86.61 | 2021-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $84.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.91 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $78.05 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.